Laura E. Scholz

Learn More
PURPOSE About 50% of prostate cancers have TMPRSS2-ERG fusions with concurrent ERG overexpression. The aim of this study was to determine whether clinical differences exist between ERG-positive and ERG-negative cancers in surgically treated patients not exposed to antihormonal therapy. A secondary aim was to search for differences between these tumor(More)
Institute of Pathology, University Medical Center Hamburg-Eppendorf, Germany Unit Cancer Genome Research, Division of Molecular Genetics, German Cancer Research Center, Heidelberg, Germany Department of Urology, University of Washington, Seattle, USA Department of Clinical Chemistry, University Medical Center Hamburg-Eppendorf, Germany Department of Tumor(More)
Tamoxifen is one of the drugs most frequently used in breast cancer therapy. It binds mainly to intracellular receptors (mainly estrogen receptor alpha, ERa) and it plays an antagonist role to β-estrogen ligands avoiding uncontrolled cellular proliferation and growth. In our laboratories we have developed a novel fluorescent tamoxifen derivative,(More)
Purpose: About 50% of prostate cancers have TMPRSS2–ERG fusions with concurrent ERG overexpression. The aim of this study was to determine whether clinical differences exist between ERG-positive and ERG-negative cancers in surgically treated patients not exposed to antihormonal therapy. A secondary aim was to search for differences between these tumor(More)
  • 1